探索肠道微生物群:其在肥胖、代谢综合征和2型糖尿病中作用的关键见解
本综述探讨肠道微生物群(GM)在肥胖、代谢综合征(MS)和2型糖尿病(T2D)中的作用机制,涉及GM多样性、宿主生理功能、菌群失调与能量提取及炎症的关联、饮食与GM的相互作用,以及药物和粪菌移植对GM的影响。现有证据主张需进一步研究以明确GM调节的治疗潜力,并强调临床试验的必要性。
要点
- GM菌群失调与能量提取增加、代谢通路改变和炎症相关,参与肥胖、MS和T2D的发生。
- 饮食 habits 与GM组成相互作用,影响微生物多样性和代谢功能。
- 现有证据主张进一步研究GM调节的治疗潜力,并强调需临床试验建立有效可持续的治疗方案。
核心结论
- 现有证据主张进一步研究以明确GM调节在减轻肥胖和代谢疾病中的治疗潜力,并强调需要临床试验来建立有效且可持续的治疗方案。
研究设计与样本
- 本综述为mini-review,阐述GM在肥胖、MS、T2D和心血管疾病中的复杂作用和机制,并探讨靶向微生物群的潜在治疗策略。
主要发现
- GM菌群失调与能量提取增加、代谢通路改变和炎症相关,促进肥胖、MS和T2D的发生。
- 饮食 habits 与GM组成之间的相互作用影响微生物多样性和代谢功能。
- 综述涉及常见药物和粪菌移植等治疗干预对GM组成的影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The gut microbiota (GM), comprising trillions of microorganisms in the gastrointestinal tract, is a key player in the development of obesity and related metabolic disorders, such as type 2 diabetes (T2D), metabolic syndrome (MS), and cardiovascular diseases. This mini-review delves into the intricate roles and mechanisms of the GM in these conditions, offering insights into potential therapeutic strategies targeting the microbiota. The review elucidates the diversity and development of the human GM, highlighting its pivotal functions in host physiology, including nutrient absorption, immune regulation, and energy metabolism. Studies show that GM dysbiosis is linked to increased energy extraction, altered metabolic pathways, and inflammation, contributing to obesity, MS, and T2D. The interplay between dietary habits and GM composition is explored, underscoring the influence of diet on microbial diversity and metabolic functions. Additionally, the review addresses the impact of common medications and therapeutic interventions like fecal microbiota transplantation on GM composition. The evidence so far advocates for further research to delineate the therapeutic potential of GM modulation in mitigating obesity and metabolic diseases, emphasizing the necessity of clinical trials to establish effective and sustainable treatment protocols.
引用
- Sasidharan Pillai S, Gagnon CA, Foster C, et al. Exploring the Gut Microbiota: Key Insights Into Its Role in Obesity, Metabolic Syndrome, and Type 2 Diabetes. J Clin Endocrinol Metab. 2024. PMID: 39040013. doi:10.1210/clinem/dgae499
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。